- Home
- HTGC vs VKTX Comparison
HTGC vs VKTX Comparison
Compare HTGC & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTGC
- VKTX
- Stock Information
- Founded
- HTGC 2003
- VKTX 2012
- Country
- HTGC United States
- VKTX United States
- Employees
- HTGC N/A
- VKTX N/A
- Industry
- HTGC Investment Managers
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- HTGC Finance
- VKTX Health Care
- Exchange
- HTGC Nasdaq
- VKTX Nasdaq
- Market Cap
- HTGC 3.5B
- VKTX 3.0B
- IPO Year
- HTGC 2005
- VKTX 2015
- Fundamental
- Price
- HTGC $17.72
- VKTX $33.32
- Analyst Decision
- HTGC Buy
- VKTX Strong Buy
- Analyst Count
- HTGC 8
- VKTX 12
- Target Price
- HTGC $21.31
- VKTX $86.42
- AVG Volume (30 Days)
- HTGC 982.6K
- VKTX 5.3M
- Earning Date
- HTGC 10-29-2025
- VKTX 10-22-2025
- Dividend Yield
- HTGC 10.49%
- VKTX N/A
- EPS Growth
- HTGC N/A
- VKTX N/A
- EPS
- HTGC 1.52
- VKTX N/A
- Revenue
- HTGC $504,002,000.00
- VKTX N/A
- Revenue This Year
- HTGC $9.13
- VKTX N/A
- Revenue Next Year
- HTGC $6.61
- VKTX N/A
- P/E Ratio
- HTGC $11.82
- VKTX N/A
- Revenue Growth
- HTGC 3.72
- VKTX N/A
- 52 Week Low
- HTGC $15.65
- VKTX $18.92
- 52 Week High
- HTGC $22.04
- VKTX $81.73
- Technical
- Relative Strength Index (RSI)
- HTGC 32.01
- VKTX 62.67
- Support Level
- HTGC $17.80
- VKTX $25.04
- Resistance Level
- HTGC $18.81
- VKTX $32.85
- Average True Range (ATR)
- HTGC 0.31
- VKTX 1.49
- MACD
- HTGC -0.12
- VKTX 1.01
- Stochastic Oscillator
- HTGC 13.14
- VKTX 88.54
About HTGC Hercules Capital Inc.
Hercules Capital Inc is a specialty finance company that provides senior secured loans to high-growth, venture capital-backed companies in various technology, life sciences, and sustainable and renewable technology industries. It invests majorly in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries, including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.